Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 2
1974 1
1975 5
1976 18
1977 8
1978 12
1979 9
1980 4
1981 9
1982 21
1983 10
1984 18
1985 6
1986 17
1987 9
1988 10
1989 15
1990 19
1991 19
1992 35
1993 30
1994 39
1995 33
1996 31
1997 29
1998 38
1999 34
2000 36
2001 21
2002 49
2003 47
2004 66
2005 52
2006 76
2007 49
2008 68
2009 80
2010 89
2011 89
2012 82
2013 83
2014 79
2015 72
2016 60
2017 70
2018 77
2019 65
2020 65
2021 49
2022 34
2023 40
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

1,785 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Stupp R, et al. JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. JAMA. 2017. PMID: 29260225 Free PMC article. Clinical Trial.
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Stupp R, et al. N Engl J Med. 2005 Mar 10;352(10):987-96. doi: 10.1056/NEJMoa043330. N Engl J Med. 2005. PMID: 15758009 Free article. Clinical Trial.
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP; Trial Investigators. Perry JR, et al. N Engl J Med. 2017 Mar 16;376(11):1027-1037. doi: 10.1056/NEJMoa1611977. N Engl J Med. 2017. PMID: 28296618 Free article. Clinical Trial.
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP. Gilbert MR, et al. N Engl J Med. 2014 Feb 20;370(8):699-708. doi: 10.1056/NEJMoa1308573. N Engl J Med. 2014. PMID: 24552317 Free PMC article. Clinical Trial.
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R. Baumert BG, et al. Lancet Oncol. 2016 Nov;17(11):1521-1532. doi: 10.1016/S1470-2045(16)30313-8. Epub 2016 Sep 27. Lancet Oncol. 2016. PMID: 27686946 Free PMC article. Clinical Trial.
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
Jakacki RI, Cohen KJ, Buxton A, Krailo MD, Burger PC, Rosenblum MK, Brat DJ, Hamilton RL, Eckel SP, Zhou T, Lavey RS, Pollack IF. Jakacki RI, et al. Neuro Oncol. 2016 Oct;18(10):1442-50. doi: 10.1093/neuonc/now038. Epub 2016 Mar 22. Neuro Oncol. 2016. PMID: 27006176 Free PMC article. Clinical Trial.
Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA, Chang JL, Oratz R, Jones A, Farrell K, Muggia F, Pavlick AC. Ott PA, et al. Chemotherapy. 2009;55(4):221-7. doi: 10.1159/000219435. Epub 2009 May 19. Chemotherapy. 2009. PMID: 19451711 Clinical Trial.
OBJECTIVE: This phase II study evaluated the efficacy and tolerability of dacarbazine in combination with thalidomide in metastatic melanoma patients. ...CONCLUSION: The addition of thalidomide to dacarbazine in metastatic melanoma yielded activity insufficient to p …
OBJECTIVE: This phase II study evaluated the efficacy and tolerability of dacarbazine in combination with thalidomide in metastatic m …
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H, Schott R, Honnorat J, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O. Chauffert B, et al. Ann Oncol. 2014 Jul;25(7):1442-1447. doi: 10.1093/annonc/mdu148. Epub 2014 Apr 9. Ann Oncol. 2014. PMID: 24723487 Free article. Clinical Trial.
Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study.
Blay JY, Schöffski P, Bauer S, Krarup-Hansen A, Benson C, D'Adamo DR, Jia Y, Maki RG. Blay JY, et al. Br J Cancer. 2019 May;120(11):1026-1032. doi: 10.1038/s41416-019-0462-1. Epub 2019 May 8. Br J Cancer. 2019. PMID: 31065111 Free PMC article. Clinical Trial.
Median OS was 12.7 versus 13.0 months for eribulin versus dacarbazine, respectively (hazard ratio [HR] = 0.93 [95% CI 0.71-1.20]; P = 0.57). Median PFS (2.2 vs 2.6 months, HR = 1.07 [95% CI 0.84-1.38]; P = 0.58) and ORR (5% vs 7%) were similar between eribulin- and daca …
Median OS was 12.7 versus 13.0 months for eribulin versus dacarbazine, respectively (hazard ratio [HR] = 0.93 [95% CI 0.71-1.20]; P = …
Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Agarwala SS, et al. Cancer. 2004 Apr 15;100(8):1692-8. doi: 10.1002/cncr.20166. Cancer. 2004. PMID: 15073858 Free article. Clinical Trial.
Cohort I compared BCG with observation and Cohort II compared BCG with a combination of BCG and dacarbazine. The primary end points were survival time and time to disease progression. RESULTS: Within Cohort I, no statistically significant difference in disease-free surviva …
Cohort I compared BCG with observation and Cohort II compared BCG with a combination of BCG and dacarbazine. The primary end points w …
1,785 results